Melinda Taschetta-Millane, Editorial Director
Melinda Taschetta-Millane, Editorial Director
Blog | Melinda Taschetta-Millane, Editorial Director | Breast Imaging | October 09, 2019

Advancements in Breast Cancer Detection

Image by laurixnh from Pixabay

Image by laurixnh from Pixabay 

Breast cancer has affected our patients, our mothers, our sisters, our colleagues, our friends … and ourselves. In this issue, we help support the message started years ago with National Breast Cancer Awareness Month and discuss the progress that has been made in the fight for a cure.

National Breast Cancer Awareness Month got its start in 1985 as a partnership between the American Cancer Society (ACS) and a leading manufacturer of oncology drugs as a commemorative campaign to raise awareness of breast cancer. Thirty-four years later, it is still a topic on the forefront of women’s health. The campaign has helped increase awareness, strongly encouraging monthly self-exams and annual mammograms. In 1993, President Bill Clinton declared the third Friday in October to be National Mammography Day, and urged clinics to offer special discounts to encourage women to get screened.

According to BreastCancer.org, “In 2019, an estimated 268,600 new cases of invasive breast cancer are expected to be diagnosed in women in the U.S., along with 62,930 new cases of in situ breast cancer. About 2,670 new cases of invasive breast cancer are expected to be diagnosed in men in 2019.” So, where do we stand today with technological advancements to help detect, treat and prevent this disease? And can artificial intelligence (AI) help?

As Greg Freiherr stated in his online-exclusive article, “AI Algorithm Detects Breast Cancer in MR Images,” the use of smart algorithms has the potential to make healthcare more efficient, and he noted a study that Sarah Eskreis-Winkler, M.D., presented on at the Society of Breast Imaging’s (SBI) annual meeting. She presented data that an algorithm trained using deep learning (DL) can reliably identify breast tumors in MR images, and stated that “in doing so, the algorithm has the potential to make radiology more efficient.” You can read the full article here: https://bit.ly/2ky92Zv.

And recently, iCAD Inc. announced MedTech Breakthrough, an independent organization that recognizes the top companies and solutions in the global health and medical technology market, selected the ProFound AI platform as the winner of its “Best New Radiology Solution” award in the 2019 MedTech Breakthrough Awards program. This solution, for digital breast tomosynthesis (DBT), is the first U.S. Food and Drug Administration (FDA)-cleared artificial intelligence solution that supports breast cancer detection in DBT. It is trained to detect malignant soft tissue densities and calcifications, and helps radiologists in breast cancer detection.

These are by far not the only examples of where breast cancer detection technology is headed. Visit ITNonline’s Women’s Health channel for a more comprehensive list of the various methods and technologies being made available to help advance this field. The future of breast cancer therapy is changing thanks to these advancements. Radiologists, you are making a difference in improving patient outcomes.

Welcome

The ITN team would also like to welcome Diane Vojcanin as vice president, group publisher, healthcare group, and Andreja Slapsys, integrated media consultant for the Midwest/West. Diane has been with parent company Scranton Gillette Communications for 14 years, having held a number of key roles, including her most recent position as vice president, group publisher of Furniture, Lighting & Decor, an award-winning brand she created. She also served as vice president of custom media, creative services and marketing, and was recognized as one of an elite group of “Top Women in Media” by FOLIO: magazine in 2018. Andreja will be a familiar face to some, having worked with ITN earlier in her career. She most recently held the role of custom media consultant for the company. Please help us welcome them into the world of radiology.

 

Related Content

ProFound AI for DBT offers superior clinical performance when compared to other commercially available breast AI systems
News | Breast Imaging | November 24, 2020
November 24, 2020 — iCAD reported that over 1,000 licenses have been sold as part of...
Densitas Inc., a global provider of A.I. technologies for digital mammography and breast screening, announced its partnership with Mammography Educators to offer the first artificial intelligence powered telehealth technologist training platform to support business continuity in mammography facilities.
News | Mammography | November 20, 2020
November 20, 2020 — Densitas Inc., a global provider of A.I.
Radiologists around the world will have access to a first-of-its-kind online breast density training tool designed to improve radiologists' ability to correctly identify women's breast density categories to comply with the Breast Imaging-Reporting and Data System (BI-RADS), thanks to a collaboration between DetectED-X and Volpara Health. 
News | Breast Density | November 19, 2020
November 19, 2020 — Radiologists around the world will have access to a first-of-its-kind online...
Reduces the complexity of reporting for screening and diagnostic MRI eams to deliver time-saving and patient safety benefits
News | MRI Breast | November 18, 2020
November 18, 2020 — ...
An interview with Professor Christiane Kuhl, M.D., director of radiology, University Hospital Aachen, Germany, on the effects on breast imaging in the COVID-19 era

Getty Images

Feature | Breast Imaging | November 12, 2020 | By Dave Fornell
The pandemic forced many elective procedures, including most areas of...
Images in a 55-year-old woman with a spiculated mass localized in the upper central quadrant (arrow in A, B, D, and E) of right breast detected with digital breast tomosynthesis (DBT) plus synthetic mammography (SM). Breast density was classified as category C with the Breast Imaging Reporting and Data System. Mass was invasive ductal carcinoma, stage I, and was estrogen and progesterone receptor positive and human epidermal growth factor receptor 2 negative. A, Image from SM in craniocaudal view. B, Single

Images in a 55-year-old woman with a spiculated mass localized in the upper central quadrant (arrow in A, B, D, and E) of right breast detected with digital breast tomosynthesis (DBT) plus synthetic mammography (SM). Breast density was classified as category C with the Breast Imaging Reporting and Data System. Mass was invasive ductal carcinoma, stage I, and was estrogen and progesterone receptor positive and human epidermal growth factor receptor 2 negative. A, Image from SM in craniocaudal view. B, Single-slice DBT image in craniocaudal view. C, Magnification of the lesion depicted in B. D, Image from SM in mediolateral oblique view. E, Single-slice DBT image in mediolateral oblique view. F, Magnification of the lesion depicted in E. Images courtesy of Radiological Society of North America

News | Breast Imaging | November 11, 2020
November 11, 2020 — ...
Hologic, Inc. announced innovative updates to its Unifi Analytics platform, a breakthrough business intelligence tool that provides mammography centers insights into technologist performance, proactive device maintenance, and business considerations.
News | Mammography | November 10, 2020
November 10, 2020 — Hologic, Inc.
Mammograms in a 51-year-old woman with invasive ductal carcinoma. The upper panels show the craniocaudal and the mediolateral oblique views. The lower panels show a close-up of the left breast area containing the lesion. The case is one of the false-negative cases included in the dataset. Accordingly, the initial screening assessment was a BI-RADS 2, meaning visible findings were judged as benign. After 1 year, the patient presented for another screening examination. This time, a focal asymmetry with associ

Mammograms in a 51-year-old woman with invasive ductal carcinoma. The upper panels show the craniocaudal and the mediolateral oblique views. The lower panels show a close-up of the left breast area containing the lesion. The case is one of the false-negative cases included in the dataset. Accordingly, the initial screening assessment was a BI-RADS 2, meaning visible findings were judged as benign. After 1 year, the patient presented for another screening examination. This time, a focal asymmetry with associated distortion within the left breast was noticed; the patient was recalled and diagnosed with a 1.5-cm mass in the upper outer quadrant of the left breast on the craniocaudal view (circle).

News | Mammography | November 04, 2020
November 4, 2020 — Artificial intelligen...